Cart
sales@molnova.com
ATPase-IN-3
CAS No. 1134203-12-5
ATPase-IN-3( —— )
Catalog No. M37359 CAS No. 1134203-12-5
ATPase-IN-3 is an ATPase (ATPase) inhibitor that can be used in the study of metabolism-related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 29 | In Stock |
|
| 5MG | 42 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 206 | In Stock |
|
| 100MG | 303 | In Stock |
|
| 200MG | 452 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameATPase-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionATPase-IN-3 is an ATPase (ATPase) inhibitor that can be used in the study of metabolism-related diseases.
-
DescriptionATPase-IN-3 is an ATPase (ATPase) inhibitor that can be used in the study of metabolism-related diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetATPase
-
RecptorATPase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1134203-12-5
-
Formula Weight266.3
-
Molecular FormulaC10H6N2O3S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS=C(NC/1=O)SC1=C/C2=CC([N+]([O-])=O)=CC=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Deslanoside
Deslanoside is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump resulting in an increase in intracellular sodium and calcium concentrations.
-
Digoxin
Digoxin is occasionally used in the treatment of various heart conditions namely atrial fibrillation atrial flutter and sometimes heart failure that cannot be controlled by other medication.
-
NDI-091143
NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay)indirectly disrupting citrate binding via an unexpected mechanism of inhibition.
